Home Newsfeeds Atlantic Equities Maintains Neutral on Biogen, Raises Price Target to $295

Atlantic Equities Maintains Neutral on Biogen, Raises Price Target to $295

Atlantic Equities analyst Steve Chesney maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $220 to $295.

December 1, 2022

1 minute read

Atlantic Equities analyst Steve Chesney maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $220 to $295.

What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals

August 21, 10:00 AM

Analysts have provided the following ratings for ANI Pharmaceuticals (NASDAQ:ANIP) within the last quarter: Bullish Somewhat Bullish Indifferent…

March 27, 9:07 AM

The banking crisis continued to dominate conversation over the weekend, especially as Deutsche Bank (NYSE: DB) gave a scare on Friday.

October 24, 3:20 PM

Mullen Automotive, Inc. (NASDAQ: MULN) shares are trading higher on Tuesday. The stock may be rebounding following recent struggles.

March 14, 6:03 AM

HC Wainwright & Co. analyst Heiko Ihle reiterates TRX Gold (AMEX:TRX) with a Buy and maintains $1.1 price target.